计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B125789-5mg |
5mg |
现货 ![]() |
| |
| B125789-25mg |
25mg |
现货 ![]() |
| |
| B125789-100mg |
100mg |
现货 ![]() |
| |
| B125789-250mg |
250mg |
现货 ![]() |
| |
| B125789-500mg |
500mg |
现货 ![]() |
| |
| B125789-1g |
1g |
现货 ![]() |
|
| 别名 | 保特佐米 | 硼替佐米 |
|---|---|
| 英文别名 | LDP 341 | BORTEZOMIB [MART.] | N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide | N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide | N-[(1R)-1-(DIHYDROXYBORYL)- |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Bortezomib (PS-341) |
| 生化机理 | 硼替佐米是第一类蛋白酶体抑制剂,可诱导骨髓瘤细胞凋亡、生长停滞并逆转化疗抗药性,而且对造血干细胞没有不可逆转的不良影响。硼替佐米对骨髓瘤、慢性淋巴细胞白血病、前列腺癌、胰腺癌和结肠癌等多种恶性肿瘤具有体外和体内活性。drμg 能迅速从血管中清除。硼替佐米在复发的套细胞淋巴瘤中显示出良好的活性,在其他 B 细胞淋巴瘤中也取得了令人鼓舞的结果。抑制多种肿瘤细胞系的增殖(IC 50 = 7 nM)。抑制 TNF 合成和 FGF 诱导的血管生成。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 26S 蛋白质体抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Bortezomib (硼替佐米; PS-341) 是20S蛋白酶体抑制剂,Ki为0.6 nM。A selective and robust 26S proteasome inhibitor Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504758619 |
|---|---|
| EC号 | 605-854-3 |
| 分子类型 | 小分子 |
| IIUPAC Name | [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid |
| INCHI | 1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 |
| InChi Key | GXJABQQUPOEUTA-RDJZCZTQSA-N |
| Smiles | B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O |
| Isomeric SMILES | B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O |
| 关联CAS | 1610526-91-4,179324-69-7 |
| NSC Number | 681239 |
| MeSH Entry Terms | 341, PS;bortezomib;LDP 341;LDP-341;LDP341;PS 341;PS-341;PS341;Velcade |
| 分子量 | 384.24 |
| Reaxy-Rn | 23876496 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=23876496&ln= |
| 溶解性 | Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol;可溶于水76 mg/l |
|---|---|
| 密度 | 1.21 |
| 敏感性 | 对光线敏感 |
| 折光率 | 1.56 |
| 沸点 | 684.30° C |
| 熔点 | 139-143°C |
| 分子量 | 384.200 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 9 |
| 精确质量Exact Mass | 384.197 Da |
| 单同位素质量Monoisotopic Mass | 384.197 Da |
| 拓扑极表面积Topological Polar Surface Area | 124.000 Ų |
| 重原子数Heavy Atom Count | 28 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 500.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS06, GHS07, GHS08, GHS09 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H300: 吞咽致命 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H361: 怀疑破坏生育力或未出生的孩子 H372: 通过长时间或反复暴露对器官造成损害 H411: 对水生生物有毒并具有长期持续影响 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P391: 收集溢出物 P302+P352: 如皮肤沾染:用水充分清洗。 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P264+P265: 处理后彻底洗手[和…]。不要触摸眼睛。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P318: 如果暴露或担心,请就医。 P337+P317: 如果眼睛刺激持续:寻求医疗帮助。 P332+P317: 如果出现皮肤刺激:请寻求医疗帮助。 P319: 如果你感到不适,请寻求医疗帮助。 |
| Merck Index | 1351 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 | |
| 分析证书 | B125789 |
| 1. Reynolds JM, El Bissati K, Brandenburg J, Günzl A, Mamoun CB. (2007) Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B.. BMC Clin Pharmacol, 7 (13). [PMID:17956613] |
| 2. Ciechanover A. (2005) Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).. Angew Chem Int Ed Engl, 44 (37): (5944-67). [PMID:16142822] |
| 3. Groll M, Berkers CR, Ploegh HL, Ovaa H. (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.. Structure, 14 (3): (451-6). [PMID:16531229] |
| 4. Bonvini P, Zorzi E, Basso G, Rosolen A. (2007) Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma.. Leukemia, 21 (4): (838-42). [PMID:17268529] |
| 5. Nakamura H, Watanabe M, Ban HS, Nabeyama W, Asai A. (2009) Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors.. Bioorg Med Chem Lett, 19 (12): (3220-4). [PMID:19428245] |
| 6. Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, Hu W, Liu Z. (2017) The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.. Lupus, 26 (9): (952-958). [PMID:28059023] |
| 7. Mazepa MA, Raval JS, Moll S, Ma A, Park YA. (2014) Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.. Br J Haematol, 164 (6): (900-2). [PMID:24345005] |
| 8. Wang Y, Zhou W, Zhang Z. (2015) Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient.. Rheumatology (Oxford), 54 (1): (194-5). [PMID:25288787] |
| 9. Jakez-Ocampo J, Atisha-Fregoso Y, Llorente L. (2015) Refractory primary Sjögren syndrome successfully treated with bortezomib.. J Clin Rheumatol, 21 (1): (31-2). [PMID:25539431] |
| 10. Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A et al.. (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.. Ann Rheum Dis, 74 (7): (1474-8). [PMID:25710470] |
| 11. Xie SC, Gillett DL, Spillman NJ, Tsu C, Luth MR, Ottilie S, Duffy S, Gould AE, Hales P, Seager BA et al.. (2018) Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.. J Med Chem, 61 (22): (10053-10066). [PMID:30373366] |
| 12. Kao CC et al.. (2022) Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules.. Mol Ther Nucleic Acids, 27 (335-348). [PMID:35024245] |
| 13. Abdin SM et al.. (2021) Nuclear factor-?B signaling inhibitors revert multidrug-resistance in breast cancer cells.. Chem Biol Interact, 340 (109450). [PMID:33775688] |
| 14. Gain C et al.. (2020) Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.. PLoS Pathog, 16 (2): (e1008105). [PMID:32092124] |
| 15. Jianhao Liu, Xiaoman Xu, Yanying Li, Jingxia Xu, Ruogang Zhao, Siwei Liu, Jingliang Wu, Li Zhang, Bo Zhang. (2023) Bortezomib-loaded mixed micelles realize a “three-in-one” effect for enhanced breast cancer treatment. Biomaterials Science, 11 (14): (4890-4906). [PMID:37306225] [10.1039/D3BM00254C] |
| 16. Chong Shi, Guo-Bin Zhang, Shu-Wang Yin. (2015) Effect of bortezomib on migration and invasion in cervical carcinoma HeLa cell. Asian Pacific Journal of Tropical Medicine, 8 (485). [PMID:26194835] [10.1016/j.apjtm.2015.05.004] |
| 17. Naikuan Fu, Yinan Zeng, Jing Zhang, Peng Zhang, Hong Zhang, Shicheng Yang, Jianhua Zhang. (2024) A Facile Strategy for PEGylated Nanoprodrug of Bortezomib with Improved Stability, Enhanced Biocompatibility, pH-Controlled Disassembly, and Release. MACROMOLECULAR BIOSCIENCE, (2400383). [PMID:39401274] [10.1002/mabi.202400383] |
| 18. Feifei Wang, Dianlong Jia, Qingcui Song, Xiaomeng Lu, Guozi Xia, Jun Li, Xiaodong Jia, Mingliang Gu, Fengjiao Yuan, Zhengping Wang, Zhangyong Xia. (2025) Co-delivery of TRAIL and bortezomib via liposomes demonstrates enhanced antitumor efficacy in vivo. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, (106602). [10.1016/j.jddst.2025.106602] |
| 19. Yuanying Li, Han Shao, Yunxiu Zhang, Qiang Liu, Changhan Yan, Xiyin Liu, Yaolan Tao, Renhao Nie, Jianhong Zhang, Qingyan Jia, Peng Li. (2025) Extracellular barrier via in situ cross-linked catechol for blocking tumor mass transport and synergistic chemotherapy. CHEMICAL ENGINEERING JOURNAL, 506 (159880). [10.1016/j.cej.2025.159880] |
| 20. Chu Xiufeng, Zhang Ting, Bukhari Ihtisham, Hu Mei, Xu Jixuan, Xing Yamin, Liang Xinfeng, Zhang Zisen, Zheng Pengyuan. (2025) Ubiquitination of gasdermin D N-terminal domain directs its membrane translocation and pore formation during pyroptosis. Cell Death & Disease, 16 (1): (1-11). [PMID:40097387] [10.1038/s41419-025-07475-6] |
| 21. Naikuan Fu, Ao Li, Jing Zhang, Peng Zhang, Hong Zhang, Shicheng Yang, Jianhua Zhang. (2025) Zwitterionic Polycatechols for Covalent Conjugation With Bortezomib and pH-Triggered Release. MACROMOLECULAR CHEMISTRY AND PHYSICS, (2400469). [10.1002/macp.202400469] |